Comparative Pharmacology
Head-to-head clinical analysis: HYDERGINE LC versus MIGERGOT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDERGINE LC versus MIGERGOT.
HYDERGINE LC vs MIGERGOT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergoloid mesylates (dihydroergotoxine) act as a partial agonist/antagonist at dopamine (D1, D2), serotonin (5-HT1, 5-HT2), and alpha-adrenergic receptors. They enhance cerebral metabolism and increase blood flow via vasodilation and neuroprotection.
Ergotamine is a partial agonist at serotonin (5-HT) receptors, particularly 5-HT1B/1D, and also exhibits agonism at alpha-adrenergic and dopamine receptors. It causes vasoconstriction of cranial blood vessels and reduces central pain transmission.
Oral, 1 mg three times daily. Titrate up to 2 mg three times daily if needed.
1 mg ergotamine tartrate and 100 mg caffeine per rectal suppository, inserted rectally at onset of headache; may repeat after 1 hour if needed, maximum 2 suppositories per headache and 5 per week.
None Documented
None Documented
Terminal elimination half-life: 12–15 hours. Clinical context: steady-state achieved in 2–3 days; allows once-daily dosing.
Ergotamine: 2 hours (initial) with terminal half-life 21-34 hours due to enterohepatic recirculation; caffeine: 3-6 hours.
Renal (80% as metabolites, <1% unchanged); biliary/fecal (20%).
Primarily hepatic metabolism (ergotamine) with 90% biliary/fecal elimination as metabolites; less than 4% renal excretion unchanged.
Category C
Category C
Ergot Alkaloid
Ergot Alkaloid